Albendazole
- PDF / 169,853 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 73 Downloads / 151 Views
1 S
Hepatotoxicity: 2 case reports In a study, 2 patients (1 woman, 1 man) aged 52 and 61 years respectively were described, who developed hepatotoxicity during treatment with albendazole for unresectable alveolar echinococcosis (AE) [routes and time to reactions onset not stated; not all outcomes stated]. The 52-year-old woman (patient no. 1), who had obstructive jaundice and had undergone liver transplantation one year prior, had been receiving albendazole 15 mg/kg/day for AE. Her anamnesis revealed continuous unspecified immunosuppressive therapy following LT. She developed hepatotoxicity with increase in hepatic transaminases. Albendazole was temporarily discontinued. Three years after LT, relapse of AE was noted with an increase in antibody titers. She underwent removal of the parasitic node in the retroperitoneal space. Albendazole 15 mg/kg/day was re-initiated in a continuous course. ELISA with Echinococcus antigens reduced to negative values within 12 months. No further relapse was noted in the following six years. The 61-year-old man (patient no. 4), who had hepatitis C related liver cirrhosis and had undergone liver transplantation one month prior, had been receiving albendazole 15 mg/kg/day for AE. His anamnesis revealed continuous unspecified immunosuppressive therapy following LT. He developed hepatotoxicity with a slight increase in hepatic aminotransferases. The man did not require any change in the albendazole regimen. Afterwards, the liver function indicators returned to the reference values. Ultrasound at six months and one year following LT showed moderate diffuse changes in his liver and new lesions in the transplant. Zavoikin VD, et al. The importance of uninterrupted albendazole treatment in patients with unresectable alveolar echinococcosis undergoing liver transplantation. Transplant 803514413 Infectious Disease 22: e13291, No. 4, Aug 2020. Available from: URL: http://doi.org/10.1111/tid.13291
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
